CEA、CA125在卵巢癌预后检测和复发诊断中的价值分析  

The Analyses of the Values of CEA and CA125 in Serum in Prognosis and Relapse of the Ovarian Cancer

作　　者：彭莉[1] 张桂霞[2] 朱传金[1] 

机构地区：[1]山东省肿瘤防治研究院检验科,山东济南250117 [2]济南市铁路中心医院检验科,山东济南250002

出　　处：《肿瘤基础与临床》2006年第5期381-382,共2页journal of basic and clinical oncology

摘　　要：目的检测卵巢癌患者在不同治疗阶段CEA、CA125含量,探讨其在卵巢癌诊断、预后及早期复发转移的临床价值。方法采用电化学发光法检测血清中CEA、CA125水平。结果卵巢癌患者血清中CEA、CA125含量明显高于卵巢癌良性疾病组和正常对照组(P<0.01),化疗后CEA、CA125的水平基本下降到正常,复发后又明显升高。结论检测不同治疗阶段CEA、CA125的含量可作为卵巢癌患者诊断、预后及复发的敏感指标。Objective To study the clinical values of determination of serum CEA and CA125 levels for the diagnosis,prognosis and relapse of patients with ovarian cancer. Methods Serum CEA,CA125 levels were detected with electrochemiluminescence immunoassay. Results The expressions of CEA and CA125 levels were significantly higher in patients with ovarian cancer than those in patients with benign ovarian disorders and controls （ P 〈 0.01 ）.The levels of CEA, CA125 of the ovarian carcinoma decreased after chemotherapy （ P 〈 0.01 ） and increase, notably after relapse. Conclusions Determination different phase of CEA and CA125 levels for the diagnosis, treatment and relapse of ovarian cancer with high specificity and sensitivity.

关 键 词：卵巢癌 化疗 CEA CA125 预后 

分 类 号：R737.31[医药卫生—肿瘤]